ReviewFrontiers in chemistry2025
Multi-targeted pharmacological actions and nanodelivery strategies of Garcinia cambogia: from molecular mechanisms to disease treatment.
Review in Frontiers in chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Garcinia cambogia (Gambogic Acid, GA) is a natural xanthone compound extracted from the resin of GA fruit, renowned for its diverse biological activities and substantial therapeutic potential. GA, a principal bioactive component of Garcinia cambogia, possesses a distinctive cage-like molecular architecture centered on an α,β-unsaturated ketone moiety. This structure is not merely a chemical signature but the fundamental source of GA's broad and integrated pharmacodynamic profile. While the multi-target nature of natural products like flavonoids has been widely documented, GA's unique polycyclic caged structure confers a different mechanism of action and a broader spectrum of activity, particularly in epigenetic reprogramming and the activation of multi-modal cell death networks. This review moves beyond a mere compilation of GA's effects to provide a systematic and critical analysis of its pharmacological landscape. We deconstruct its mechanisms along three integrated dimensions: (i) a molecular-level characterization of GA-regulated signaling pathways, emphasizing its multi-target synergy; (ii) an empirical evaluation of its therapeutic efficacy across cancer and inflammatory diseases, critically appraising both promises and limitations of current evidence; and (iii) an evidence-based discussion on overcoming translational barriers, with a focal point on how innovative nanodelivery strategies are pivotal in resolving GA's pharmacokinetic challenges. By directly comparing GA with other natural products (e.g., flavonoids) in terms of structure-activity relationships and translational potential, we highlight its unique position in the natural product pharmacopeia. We conclude that the future of GA research lies in the integration of multi-omics approaches with precision drug delivery systems, a synergistic strategy that will effectively bridge the gap between its robust mechanistic underpinnings and successful clinical application.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.